284 related articles for article (PubMed ID: 33355035)
1. Epidemiology and treatment patterns for locally advanced or metastatic urothelial carcinoma: a systematic literature review and gap analysis.
Hepp Z; Shah SN; Smoyer K; Vadagam P
J Manag Care Spec Pharm; 2021 Feb; 27(2):240-255. PubMed ID: 33355035
[No Abstract] [Full Text] [Related]
2. Clinical evidence for the first-line treatment of advanced urothelial carcinoma: Current paradigms and emerging treatment options.
Koufopoulou M; Miranda PAP; Kazmierska P; Deshpande S; Gaitonde P
Cancer Treat Rev; 2020 Sep; 89():102072. PubMed ID: 32769039
[TBL] [Abstract][Full Text] [Related]
3. Real-world burden of illness and unmet need in locally advanced or metastatic urothelial carcinoma following discontinuation of PD-1/L1 inhibitor therapy: A Medicare claims database analysis.
Morgans AK; Hepp Z; Shah SN; Shah A; Petrilla A; Small M; Sonpavde G
Urol Oncol; 2021 Oct; 39(10):733.e1-733.e10. PubMed ID: 34238657
[TBL] [Abstract][Full Text] [Related]
4. Real-world treatment patterns and clinical outcomes with first-line therapy in patients with locally advanced/metastatic urothelial carcinoma by cisplatin-eligibility.
Morgans AK; Galsky MD; Wright P; Hepp Z; Chang N; Willmon CL; Sesterhenn S; Liu Y; Sonpavde GP
Urol Oncol; 2023 Aug; 41(8):357.e11-357.e21. PubMed ID: 37208230
[TBL] [Abstract][Full Text] [Related]
5. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial.
Yu EY; Petrylak DP; O'Donnell PH; Lee JL; van der Heijden MS; Loriot Y; Stein MN; Necchi A; Kojima T; Harrison MR; Hoon Park S; Quinn DI; Heath EI; Rosenberg JE; Steinberg J; Liang SY; Trowbridge J; Campbell M; McGregor B; Balar AV
Lancet Oncol; 2021 Jun; 22(6):872-882. PubMed ID: 33991512
[TBL] [Abstract][Full Text] [Related]
6. Clinical and Patient-Reported Outcomes of Advanced Urothelial Carcinoma Following Discontinuation of PD-1/L1 Inhibitor Therapy.
Morgans AK; Grewal S; Hepp Z; Fuldeore R; Odak S; Macahilig C; Shillington AC; Sonpavde G
Clin Genitourin Cancer; 2022 Dec; 20(6):543-552. PubMed ID: 36088235
[TBL] [Abstract][Full Text] [Related]
7. Avelumab as First-Line Maintenance Treatment in Locally Advanced or Metastatic Urothelial Carcinoma.
Mansinho A; Cruz A; Marconi L; Pinto C; Augusto I
Adv Ther; 2023 Oct; 40(10):4134-4150. PubMed ID: 37608243
[TBL] [Abstract][Full Text] [Related]
8. First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis.
Mori K; Pradere B; Moschini M; Mostafaei H; Laukhtina E; Schuettfort VM; Sari Motlagh R; Soria F; Teoh JYC; Egawa S; Powles T; Shariat SF;
Eur J Cancer; 2021 Jul; 151():35-48. PubMed ID: 33962359
[TBL] [Abstract][Full Text] [Related]
9. Treatment Patterns and Attrition With Lines of Therapy for Advanced Urothelial Carcinoma in the US.
Mathew Thomas V; Jo Y; Tripathi N; Roy S; Chigarira B; Narang A; Gebrael G; Hage Chehade C; Sayegh N; Galarza Fortuna G; Ji R; Campbell P; Li H; Agarwal N; Gupta S; Swami U
JAMA Netw Open; 2024 May; 7(5):e249417. PubMed ID: 38696168
[TBL] [Abstract][Full Text] [Related]
10. The Rapidly Evolving Landscape of First-Line Targeted Therapy in Metastatic Urothelial Cancer: A Systematic Review.
Lavoie JM; Sridhar SS; Ong M; North S; Alimohamed N; McLeod D; Eigl BJ
Oncologist; 2021 Aug; 26(8):e1381-e1394. PubMed ID: 34028134
[TBL] [Abstract][Full Text] [Related]
11. Research progress on PD-1 and PD-L1 inhibitors in the treatment of metastatic urothelial carcinoma.
Tang Q; Li S; Huang G; Liu H
Int Immunopharmacol; 2023 Jun; 119():110158. PubMed ID: 37062259
[TBL] [Abstract][Full Text] [Related]
12. First-line avelumab for patients with PD-L1-positive metastatic or locally advanced urothelial cancer who are unfit for cisplatin.
Iacovelli R; Ciccarese C; Brunelli M; Battelli N; Buttigliero C; Caserta C; Buti S; Santini D; Carella C; Galli L; Verri E; Ermacora P; Merler S; Masini C; De Vivo R; Milesi L; Spina F; Rizzo M; Sperduti I; Fornarini G; Tortora G
Ann Oncol; 2022 Nov; 33(11):1179-1185. PubMed ID: 35926813
[TBL] [Abstract][Full Text] [Related]
13. Recent developments in the treatment of advanced bladder cancer.
Godwin JL; Hoffman-Censits J; Plimack E
Urol Oncol; 2018 Mar; 36(3):109-114. PubMed ID: 29395952
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of Pembrolizumab versus Carboplatin-based Chemotherapy as First-line Treatment of PD-L1-positive Locally Advanced or Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Therapy in the United States.
Hale O; Patterson K; Lai Y; Meng Y; Li H; Godwin JL; Homet Moreno B; Mamtani R
Clin Genitourin Cancer; 2021 Feb; 19(1):e17-e30. PubMed ID: 32826180
[TBL] [Abstract][Full Text] [Related]
15. Anti-Programmed Cell Death 1/Ligand 1 (PD-1/PD-L1) Antibodies for the Treatment of Urothelial Carcinoma: State of the Art and Future Development.
Powles T; Necchi A; Rosen G; Hariharan S; Apolo AB
Clin Genitourin Cancer; 2018 Apr; 16(2):117-129. PubMed ID: 29325739
[TBL] [Abstract][Full Text] [Related]
16. FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy.
Suzman DL; Agrawal S; Ning YM; Maher VE; Fernandes LL; Karuri S; Tang S; Sridhara R; Schroeder J; Goldberg KB; Ibrahim A; McKee AE; Pazdur R; Beaver JA
Oncologist; 2019 Apr; 24(4):563-569. PubMed ID: 30541754
[TBL] [Abstract][Full Text] [Related]
17. Molecular predictors of response to PD-1/PD-L1 inhibition in urothelial cancer.
Stühler V; Maas JM; Bochem J; da Costa IA; Todenhöfer T; Stenzl A; Bedke J
World J Urol; 2019 Sep; 37(9):1773-1784. PubMed ID: 30374610
[TBL] [Abstract][Full Text] [Related]
18. Second Line Chemotherapy for Advanced and Metastatic Urothelial Carcinoma: Vinflunine and Beyond-A Comprehensive Review of the Current Literature.
Oing C; Rink M; Oechsle K; Seidel C; von Amsberg G; Bokemeyer C
J Urol; 2016 Feb; 195(2):254-63. PubMed ID: 26410730
[TBL] [Abstract][Full Text] [Related]
19. Expression of Programmed Cell Death Ligand 1 as a Predictive Biomarker in Metastatic Urothelial Carcinoma Patients Treated with First-line Immune Checkpoint Inhibitors Versus Chemotherapy: A Systematic Review and Meta-analysis.
Rizzo A; Mollica V; Massari F
Eur Urol Focus; 2022 Jan; 8(1):152-159. PubMed ID: 33516645
[TBL] [Abstract][Full Text] [Related]
20. The 27-gene IO score is associated with efficacy of PD-1/L1 inhibitors independent of FGFR expression in a real-world metastatic urothelial carcinoma cohort.
Nielsen TJ; Varga MG; Cronister CT; Ring BZ; Seitz RS; Ross DT; Schweitzer BL; McGregor K
Cancer Immunol Immunother; 2023 Jul; 72(7):2075-2086. PubMed ID: 36806983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
